Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-133891

Published: 2020

Journal Articles

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Elisa De Togni, BA, Miriam Y Kim, MD, Matt L Cooper, PhD, Julie Ritchey, Julie O'Neal, PhD, Jessica Niswonger, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2205.

https://doi.org/10.1182/blood-2018-99-113438

Published: 2018

Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 1000.

https://doi.org/10.1182/blood.V128.22.1000.1000

Published: 2016

Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 766.

https://doi.org/10.1182/blood.V128.22.766.766

Published: 2016

Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 652.

https://doi.org/10.1182/blood.V128.22.652.652

Published: 2016

Journal Articles

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, David L Porter, MD, Carl H. June, MD, Saar I Gill, MBBS, PhD

Blood (2015) 126 (23): 852.

https://doi.org/10.1182/blood.V126.23.852.852

Published: 2015

Journal Articles

Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis

Sikander Ailawadhi, MD, Dongyun Yang, PhD, Gaurav Patel, MSHA, Yin Zhang, MD, Ibrahim T. Aldoss, MBBS, Miriam Y. Kim, MD, Asher Chanan-Khan, MD

Blood (2011) 118 (21): 845.

https://doi.org/10.1182/blood.V118.21.845.845

Published: 2011

Journal Articles

Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study.

Ranjana Advani, MD, K. Hymes, MD, B. Pohlman, MD, E. Jacobsen, MD, J. McDonnell, MD, R. Belt, MD, A. Lerner, MD, Y. Kim, MD, R. Mundis, MD, T. Mansfield, PhD, P. Buhl-Jensen, MD, C.E. Ooi, PhD, M. Duvic, MD, F. Foss, MD

Blood (2007) 110 (11): 3453.

https://doi.org/10.1182/blood.V110.11.3453.3453

Published: 2007

Journal Articles

Mechanical Ventricular Assistance Rescues Endocardial Thrombomodulin Expression and May Restore Thromboresistance.

Antony Y. Kim, MD, Elizabeth Favre, Xiaojing Tian, Jonathan Paul, Jaishankar Raman, Jonathan L. Miller, MD, PhD

Blood (2005) 106 (11): 1639.

https://doi.org/10.1182/blood.V106.11.1639.1639

Published: 2005

Journal Articles

Binding Properties of a Human Anti-Ib ScFv Antibody (HIb-1) to Native, Recombinant, and Transgenicially Expressed Human Platelet GP Ibα Antigen.

Antony Y. Kim, MD, George Bell, MD, Joshua Lovelock, MD, Elizabeth G. Favre, BS, Tapan K. Biswas, PhD, Mohammed Yousef, PhD, Jonathan L. Miller, MD, PhD

Blood (2005) 106 (11): 4162.

https://doi.org/10.1182/blood.V106.11.4162.4162

Published: 2005

NARROW

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis

Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study.

Mechanical Ventricular Assistance Rescues Endocardial Thrombomodulin Expression and May Restore Thromboresistance.

Binding Properties of a Human Anti-Ib ScFv Antibody (HIb-1) to Native, Recombinant, and Transgenicially Expressed Human Platelet GP Ibα Antigen.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only